Adjunct to diet when response to diet & exercise is inadequate. Adult patients w/ an increased risk of atherosclerosis, CV disease based on the presence of risk markers eg, elevated hsCRP level, age, HTN, low HDL-C, smoking or family history of premature CHD. Reduce total mortality & the risk of major CV events (CV death, stroke, MI, unstable angina or arterial revascularization). Reduce elevated LDL-C, total-C, triglycerides & increase HDL-C in patients w/ primary hypercholesterolemia (heterozygous familial & nonfamilial) & mixed dyslipidemia (Fredrickson types IIa/IIb). Treatment of primary dysbetalipoproteinemia (Fredrickson type III hyperlipoproteinemia), isolated hypertriglyceridemia (Fredrickson type IV hyperlipidemia). Reduce total-C & LDL-C in patients w/ homozygous familial hypercholesterolemia as adjunct to diet & other lipid-lowering treatments (eg, LDL apheresis) or alone if such treatments are unavailable. Slow or delay atherosclerosis progression. Reduce total-C, LDL-C & Apo B in childn & adolescents 10-17 yr w/ heterozygous familial hypercholesterolemia.
Sign Out
